Pliant Therapeutics, Inc.
PLRX
$1.38
-$0.09-6.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -97.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -97.46% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -100.00% | -97.46% |
| SG&A Expenses | 0.49% | 1.95% | 0.10% | 14.80% | 29.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.66% | 22.96% | 24.73% | 26.84% | 29.06% |
| Operating Income | -20.81% | -24.01% | -27.26% | -30.85% | -37.82% |
| Income Before Tax | -28.56% | -30.35% | -29.88% | -28.38% | -28.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.56% | -30.35% | -29.88% | -28.38% | -28.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.56% | -30.35% | -29.88% | -28.38% | -28.60% |
| EBIT | -20.81% | -24.01% | -27.26% | -30.85% | -37.82% |
| EBITDA | -20.93% | -24.10% | -27.38% | -31.08% | -38.26% |
| EPS Basic | -26.35% | -26.44% | -20.25% | -12.70% | 0.07% |
| Normalized Basic EPS | -26.36% | -26.44% | -20.49% | -12.91% | -0.12% |
| EPS Diluted | -26.35% | -26.44% | -20.25% | -12.70% | 0.07% |
| Normalized Diluted EPS | -26.36% | -26.44% | -20.49% | -12.91% | -0.12% |
| Average Basic Shares Outstanding | 1.78% | 3.12% | 7.82% | 13.92% | 27.23% |
| Average Diluted Shares Outstanding | 1.78% | 3.12% | 7.82% | 13.92% | 27.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |